secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-01-24T23:59:59+00:00
Accession:  0001213900-23-004843
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics posts updated corporate presentation highlighting c-Kit approach and briquilimab
--------------------------------------------------------------------------------

- Filed an updated corporate presentation (Exhibit 99.1) dated January 2023 under Item 7.01.
- Presentation titled 'Harnessing the Power of Jasper’s Differentiated c-Kit Therapeutic Approach'.
- Briquilimab described as an investigative drug not approved for any indication.
- No specific financial or clinical updates provided in the furnished exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023004843/0001213900-23-004843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023004843/ea172105-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-004843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer